You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

10 Items
Other Name(s): Treanda® (Lundbeck Canada Inc.)
Funding:
New Drug Funding Program
  • Bendamustine - First Line - Chronic Lymphocytic Leukemia
  • Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
  • Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Apr 2017
Other Name(s): Avastin® (Hoffmann-LaRoche)
Funding:
New Drug Funding Program
  • Bevacizumab - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
  • Bevacizumab in combination with paclitaxel and carboplatin - Front-line Treatment Ovarian Fallopian Tube and Primary Peritoneal Cancer
  • Bevacizumab - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Bevacizumab for Platinum-Resistant Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer
Nov 2017
Other Name(s): Casodex® (multiple brands available)
Funding:
ODB - General Benefit
  • bicalutamide
Nov 2017
Other Name(s): Blenoxane® (multiple brands available)
Aug 2016
Other Name(s): Blincyto (Amgen Canada)
Funding:
New Drug Funding Program
  • Blinatumomab - Acute Lymphoblastic Leukemia
Oct 2017
Other Name(s): Velcade® (multiple brands available)
Funding:
New Drug Funding Program
  • Bortezomib - Previously Untreated - Multiple Myeloma
  • Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
  • Bortezomib - Relapsed or Refractory Multiple Myeloma
Apr 2016
Other Name(s): Bosulif® (Pfizer)
Funding:
Exceptional Access Program
  • bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Nov 2017
Other Name(s): Adcetris® (Seattle Genetics Inc.)
Funding:
New Drug Funding Program
  • Brentuximab - Hodgkin's Lymphoma
  • Brentuximab - Systemic Anaplastic Large Cell Lymphoma
Nov 2017
Other Name(s): Suprefact® (Sanofi-Aventis); Suprefact Depot® (Sanofi-Aventis); Suprefact Nasal Spray® (Sanofi-Aventis)
Funding:
ODB - General Benefit
  • buserelin
Aug 2015
Other Name(s): Busulfex® (Otsuka); Myleran® (Aspen Pharmacare)
Funding:
ODB - General Benefit
  • busulfan - oral tablets
Aug 2016